Guggenheim analyst Yatin Suneja reiterated a Buy rating on Tourmaline Bio (NASDAQ: TRML).The analyst commented: "On Friday, TRML hosted a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE